Factor VIII desensitising patch - DBV Technologies/INSERM

Drug Profile

Factor VIII desensitising patch - DBV Technologies/INSERM

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator DBV Technologies; INSERM
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypersensitivity

Most Recent Events

  • 04 Mar 2016 Pharmacodynamics data from a preclinical trial in Hypersensitivity to Factor VIII in Haemophilia A presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
  • 22 Oct 2013 Preclinical trials in Hypersensitivity to Factor VIII in Haemophilia A in France (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top